← All trials
NCT04844775
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2021
- Primary completion
- Jun 30, 2022
- Completion date
- Jun 30, 2023
- First posted
- Apr 14, 2021
- Last posted
- Apr 14, 2021
- Enrollment
- 70
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Government of FranceLead sponsor
- CHU Henri MondorCollaborator
- University of LondonCollaborator
- Medical Research CouncilCollaborator
- European CommissionCollaborator
- EuroVacc FoundationCollaborator
- Imperial College LondonCollaborator
- Government of SwitzerlandCollaborator
- University of LondonCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.